Tonix Pharmaceuticals Announces Publication In Microorganisms Of Technology That Expands Company's Capabilities In Generating Potential Therapeutic Fully Human Antibodies Against SARS-CoV-2 And Other Pathogens
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals announced the publication of a research paper in Microorganisms, highlighting their high-throughput, high-content imaging technology for screening convalescent sera to generate neutralizing antibodies against SARS-CoV-2 variants. The study underscores Tonix's R&D capabilities, including a COVID-19 vaccine selected by NIH for Project NextGen and a host-directed anti-viral program awarded a DoD/DTRA contract for up to $34 million.
August 06, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals' publication in Microorganisms highlights their advanced technology for screening COVID-19 antibodies, enhancing their R&D reputation. The company also secured a $34M DoD/DTRA contract, which could positively impact their revenue and stock price.
The publication in a peer-reviewed journal and the $34M DoD/DTRA contract highlight Tonix's strong R&D capabilities and potential revenue growth, likely boosting investor confidence and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100